Glucuronidation of fimasartan, a new angiotensin receptor antagonist, is mainly mediated by UGT1A3
Authors:
- Yang-Weon KimYKYang-Weon Kim
- Hyo-Ji KimHKHyo-Ji Kim
- Ho-Jung ShinHSHo-Jung Shin
- Jae-Gook ShinJSJae-Gook Shin
- Kwang Hee KimKKKwang Hee Kim
- Yong Ha ChiYCYong Ha Chi
- Soo Heui PaikSPSoo Heui Paik
- Dong-Hyun KimDong-Hyun Kim
- 18 July 2014
- journal article
- Published by Taylor & Francis in Xenobiotica
- Vol. 45 (1) , 10-18
Abstract
1. Fimasartan is an angiotensin receptor II antagonist used to treat patients with hypertension. This drug is mainly excreted into bile as either the parent compound or a glucuronide conjugate. In this study, we examined the glucuronidation of fimasartan and characterized the UDP-glucuronosyltransferases (UGTs) responsible for the glucuronidation. 2. Only one type of fimasartan glucuronide was observed after incubation with pooled human liver microsomes (HLMs) and was identified as an N2-glucuronide based on comparison with an authentic standard. 3. Among the 12 UGT isoforms tested, UGT1A1, UGT1A3 and UGT2B7 showed catalytic activity toward fimasartan glucuronidation. The intrinsic clearance (CLint) of UGT1A3 was 68.5- and 21.4-fold higher than that of UGT1A1 and UGT2B7, respectively, and the estimated relative contribution of UGT1A3 in human liver was 94.1%. Both chemical inhibition and correlation studies demonstrated that fimasartan glucuronidation activity in HLMs was significantly related with UGT1A3 activity. Fimasartan glucuronide was identified as a substrate for P-glycoprotein (Pgp) and breast cancer response protein (BCRP). 4. These findings collectively indicate that UGT1A3 is the major UGT isoform responsible for the glucuronidation of fimasartan, and this glucuronide is excreted from hepatocytes via MDR1 and BCRP.Keywords
This publication has 30 references indexed in Scilit:
- Targeted Precise Quantification of 12 Human Recombinant Uridine-Diphosphate Glucuronosyl Transferase 1A and 2B Isoforms Using Nano-Ultra-High-Performance Liquid Chromatography/Tandem Mass Spectrometry with Selected Reaction MonitoringDrug Metabolism and Disposition, 2013
- Targeted Quantitative Proteomics for the Analysis of 14 UGT1As and -2Bs in Human Liver Using NanoUPLC–MS/MS with Selected Reaction MonitoringJournal of Proteome Research, 2013
- The Effect of Fimasartan, an Angiotensin Receptor Type 1 Blocker, on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Korean Male Volunteers: A One-Sequence, Two-Period Crossover Clinical TrialClinical Therapeutics, 2012
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Fimasartan Following Single and Repeated Oral Administration in the Fasted and Fed States in Healthy SubjectsAmerican Journal of Cardiovascular Drugs, 2011
- Validated assay for studying activity profiles of human liver UGTs after drug exposure: inhibition and induction studiesAnalytical and Bioanalytical Chemistry, 2010
- The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartanBiochemical Pharmacology, 2008
- Interactions between Human UGT1A1, UGT1A4, and UGT1A6 Affect Their Enzymatic ActivitiesDrug Metabolism and Disposition, 2007
- Effects of Coexpression of UGT1A9 on Enzymatic Activities of Human UGT1A IsoformsDrug Metabolism and Disposition, 2007
- DETERMINATION OF DRUG GLUCURONIDATION AND UDP-GLUCURONOSYLTRANSFERASE SELECTIVITY USING A 96-WELL RADIOMETRIC ASSAYDrug Metabolism and Disposition, 2005
- Isoform‐Selective Probe Substrates for In Vitro Studies of Human UDP‐Glucuronosyltransferases2005